Scutellarein inhibits the development of colon cancer via CDC4‑mediated RAGE ubiquitination

Li,Yuanzhi; Wang,Jundong; Zhong,Sen; Li,Jun; Du,Weiliang

doi:10.3892/ijmm.2020.4496

Scutellarein inhibits the development of colon cancer via CDC4‑mediated RAGE ubiquitination

Authors:
- Yuanzhi Li
- Jundong Wang
- Sen Zhong
- Jun Li
- Weiliang Du
View Affiliations

Affiliations: Traditional Chinese Medicine Department, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan 646000, P.R. China, Department of Gastroenterology, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan 610000, P.R. China, Department of Infection, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan 610000, P.R. China
Published online on: February 10, 2020 https://doi.org/10.3892/ijmm.2020.4496
Pages: 1059-1072
Copyright: © Li et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Scutellarein has been identified to serve an anti‑tumor function in human colon cancer, but the underlying mechanisms remain largely unclear. The present study further investigated the effect and mechanism of scutellarein, extracted from wild chrysanthemum, in the progression of colon cancer. MTT, clone formation, flow cytometry and tumor‑bearing mice assays were used to detect cell viability, clone formation, apoptosis and tumorigenesis, respectively. Western blot and quantitative PCR assays were performed for protein and mRNA expression detection. The results revealed that, compared with the control group, scutellarein treatment significantly inhibited the viability and induced the apoptosis of colon cancer cells (P<0.05), with significant decreases in receptor for advanced glycosylation end products (RAGE) protein expression and stability and an increase in RAGE ubiquitination (P<0.05). However, the effects of scutellarein exerted in cell apoptosis and viability were rescued by RAGE overexpression, and accelerated by RAGE knockdown. Additionally, it was observed that scutellarein treatment induced a significant increase in the expression of cell division control protein 4 (CDC4) compared with the control group (P<0.05), which was then verified to interact with RAGE protein and mediate its ubiquitination. Overexpression of CDC4 inhibited colon cancer cell viability and promoted the apoptosis of SW480 and T84 cells, whereas this function was weakened when RAGE was overexpressed. Furthermore, CDC4 downregulation significantly neutralized scutellarein functions in promoting cell apoptosis and inhibiting cell viability and tumorigenesis in colon cancer cells compared with the scutellarein group (P<0.05). In conclusion, the present study revealed that scutellarein inhibited the development of colon cancer through upregulating CDC4‑mediated RAGE ubiquitination.

View Figures

View References

1	Labianca R, Beretta GD, Kildani B, Milesi L, Merlin F, Mosconi S, Pessi MA, Prochilo T, Quadri A, Gatta G, et al: Colon cancer. Crit Rev Oncol Hematol. 74:106–133. 2010. View Article : Google Scholar : PubMed/NCBI
2	Freeman HJ: Early stage colon cancer. World J Gastroenterol. 19:8468–8473. 2013. View Article : Google Scholar :
3	Orangio GR: The economics of colon cancer. Surg Oncol Clin N Am. 27:327–347. 2018. View Article : Google Scholar : PubMed/NCBI
4	Zhang Y, Shi J, Huang H, Ren J, Li N and Dai M: Burden of colorectal cancer in China. Zhonghua Liu Xing Bing Xue Za Zhi. 36:709–714. 2015.In Chinese. PubMed/NCBI
5	Sun S, Jiang P, Su W, Xiang Y, Li J, Zeng L and Yang S: Wild chrysanthemum extract prevents UVB radiation-induced acute cell death and photoaging. Cytotechnology. 68:229–240. 2016. View Article : Google Scholar :
6	Yang WS, Kim D, Yi YS, Kim JH, Jeong HY, Hwang K, Kim JH, Park J and Cho JY: AKT-targeted anti-inflammatory activity of the methanol extract of Chrysanthemum indicum var. albescens J Ethnopharmacol. 201:82–90. 2017. View Article : Google Scholar
7	Deng Y, Jiang J, Chen S, Teng N, Song A, Guan Z, Fang W and Chen F: Combination of multiple resistance traits from wild relative species in Chrysanthemum via trigeneric hybridization. PLoS One. 7:302012. View Article : Google Scholar
8	Hassanpouraghdam MB: Flowerhead volatile oil composition of soilless culture-grown Chrysanthemum balsamita L. Nat Prod Res. 23:672–677. 2009. View Article : Google Scholar : PubMed/NCBI
9	Shi X, Chen G and Liu X, Qiu Y, Yang S, Zhang Y, Fang X, Zhang C and Liu X: Scutellarein inhibits cancer cell metastasis in vitro and attenuates the development of fibrosarcom in vivo. Int J Mol Med. 35:31–38. 2015. View Article : Google Scholar
10	Cheng CY, Hu CC, Yang HJ, Lee MC and Kao ES: Inhibitory effects of scutellarein on proliferation of human lung cancer A549 cells through ERK and NFκB mediated by the EGFR pathway. Chin J Physiol. 57:182–187. 2014. View Article : Google Scholar : PubMed/NCBI
11	Parajuli P, Joshee N, Rimando AM, Mittal S and Yadav AK: In vitro antitumor mechanisms of various Scutellaria extracts and constituent flavonoids. Planta Med. 75:41–48. 2009. View Article : Google Scholar
12	Guo F, Yang F and Zhu YH: Scutellarein from Scutellaria barbata induces apoptosis of human colon cancer HCT116 cells through the ROS-mediated mitochondria-dependent pathway. Nat Prod Res. 33:2372–2375. 2019. View Article : Google Scholar
13	Goh D, Lee YH and Ong ES: Inhibitory effects of a chemically standardized extract from Scutellaria barbata in human colon cancer cell lines, LoVo. J Agric Food Chem. 53:8197–8204. 2005. View Article : Google Scholar : PubMed/NCBI
14	Behzad MM, Asnafi AA, Jaseb K, Jalali Far MA and Saki N: Expression of CD markers' in immune thrombocytopenic purpura: Prognostic approaches. APMIS. 125:1042–1055. 2017. View Article : Google Scholar : PubMed/NCBI
15	Bacher P and Scheffold A: Flow-cytometric analysis of rare antigen-specific T cells. Cytometry A. 83:692–701. 2013. View Article : Google Scholar : PubMed/NCBI
16	Tripathi SC, Fahrmann JF, Celiktas M, Aguilar M, Marini KD, Jolly MK, Katayama H, Wang H, Murage EN, Dennison JB, et al: MCAM mediates chemoresistance in small-cell lung cancer via the PI3K/AKT/SOX2 signaling pathway. Cancer Res. 77:4414–4425. 2017. View Article : Google Scholar : PubMed/NCBI
17	Wang Z and Yan X: CD146, a multi-functional molecule beyond adhesion. Cancer Lett. 330:150–162. 2013. View Article : Google Scholar
18	Zhang H, Zhang J, Wang Z, Lu D, Feng J, Yang D, Chen X and Yan X: CD146 is a potential marker for the diagnosis of malignancy in cervical and endometrial cancer. Oncol Lett. 5:1189–1194. 2013. View Article : Google Scholar : PubMed/NCBI
19	Tanida S, Mizoshita T, Mizushima T, Sasaki M, Shimura T, Kamiya T, Kataoka H and Joh T: Involvement of oxidative stress and mucosal addressin cell adhesion molecule-1 (MAdCAM-1) in inflammatory bowel disease. J Clin Biochem Nutr. 48:112–116. 2011. View Article : Google Scholar : PubMed/NCBI
20	Truffi M, Colombo M, Peñaranda-Avila J, Sorrentino L, Colombo F, Monieri M, Collico V, Zerbi P, Longhi E, Allevi R, et al: Nano-targeting of mucosal addressin cell adhesion molecule-1 identifies bowel inflammation foci in murine model. Nanomedicine (Lond). 12:1547–1560. 2017. View Article : Google Scholar
21	Logsdon CD, Fuentes MK, Huang EH and Arumugam T: RAGE and RAGE ligands in cancer. Curr Mol Med. 7:777–789. 2007. View Article : Google Scholar
22	Palanissami G and Paul SFD: RAGE and Its ligands: Molecular interplay between glycation, inflammation, and hallmarks of cancer-a review. Horm Cancer. 9:295–325. 2018. View Article : Google Scholar : PubMed/NCBI
23	Fuentes MK, Nigavekar SS, Arumugam T, Logsdon CD, Schmidt AM, Park JC and Huang EH: RAGE activation by S100P in colon cancer stimulates growth, migration, and cell signaling pathways. Dis Colon Rectum. 50:1230–1240. 2007. View Article : Google Scholar : PubMed/NCBI
24	Foot N, Henshall T and Kumar S: Ubiquitination and the regulation of membrane proteins. Physiol Rev. 97:253–281. 2017. View Article : Google Scholar
25	Swatek KN and Komander D: Ubiquitin modifications. Cell Res. 26:399–422. 2016. View Article : Google Scholar : PubMed/NCBI
26	Zhou MJ, Chen FZ and Chen HC: Ubiquitination involved enzymes and cancer. Med Oncol. 31:932014. View Article : Google Scholar : PubMed/NCBI
27	Jin X, Yang C, Fan P, Xiao J, Zhang W, Zhan S, Liu T, Wang D and Wu H: CDK5/FBW7-dependent ubiquitination and degradation of EZH2 inhibits pancreatic cancer cell migration and invasion. J Biol Chem. 292:6269–6280. 2017. View Article : Google Scholar : PubMed/NCBI
28	Gallo LH, Ko J and Donoghue DJ: The importance of regulatory ubiquitination in cancer and metastasis. Cell Cycle. 16:634–648. 2017. View Article : Google Scholar : PubMed/NCBI
29	Yan C, Su H, Song X, Cao H, Kong L and Cui W: Smad ubiquitination regulatory factor 1 (Smurf1) promotes thyroid cancer cell proliferation and migration via ubiquitin-dependent degradation of kisspeptin-1. Cell Physiol Biochem. 49:2047–2059. 2018. View Article : Google Scholar : PubMed/NCBI
30	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar
31	Xin B, He X, Wang J, Cai J, Wei W, Zhang T and Shen X: Nerve growth factor regulates CD133 function to promote tumor cell migration and invasion via activating ERK1/2 signaling in pancreatic cancer. Pancreatology. 16:1005–1014. 2016. View Article : Google Scholar : PubMed/NCBI
32	Huang XW, Xu Y, Sui X, Lin H, Xu JM, Han D, Ye DD, Lv GF, Liu YX, Qu XB and Duan MH: Scutellarein suppresses Aβ-induced memory impairment via inhibition of the NF-κB pathway in vivo an in vitro. Oncol Lett. 17:5581–5589. 2019.PubMed/NCBI
33	Tian X, Chang L, Ma G, Wang T, Lv M, Wang Z, Chen L, Wang Y, Gao X and Zhu Y: Delineation of platelet activation pathway of scutellarein revealed its intracellular target as protein kinase C. Biol Pharm Bull. 39:181–191. 2016. View Article : Google Scholar
34	Thirusangu P, Vigneshwaran V, Vijay Avin BR, Rakesh H, Vikas HM and Prabhakar BT: Scutellarein antagonizes the tumorigenesis by modulating cytokine VEGF mediated neoangiogenesis and DFF-40 actuated nucleosomal degradation. Biochem Biophys Res Commun. 484:85–92. 2017. View Article : Google Scholar : PubMed/NCBI
35	Labianca R, Nordlinger B, Beretta GD, Mosconi S, Mandalà M, Cervantes A and Arnold D; ESMO Guidelines Working Group: Early colon cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 24(Suppl 6): vi64–vi72. 2013. View Article : Google Scholar : PubMed/NCBI
36	Bosman FT and Yan P: Molecular pathology of colon cancer. Pol J Pathol. 65(4 Suppl 1): S1–S11. 2014.In Polish.
37	Wang F, Yang B, Zhao Y, Liao X, Gao C, Jiang R, Han B, Yang J, Liu M and Zhou R: Host-guest inclusion system of scutellarein with 2-hydroxypropyl-beta-cyclodextrin: Preparation, characterization, and anticancer activity. J Biomater Sci Polym Ed. 25:594–607. 2014. View Article : Google Scholar : PubMed/NCBI
38	van Zoelen MA, Achouiti A and van der Poll T: RAGE during infectious diseases. Front Biosci (Schol Ed). 3:1119–1132. 2011. View Article : Google Scholar
39	Lee TW, Kao YH, Chen YJ, Chao TF and Lee TI: Therapeutic potential of vitamin D in AGE/RAGE-related cardiovascular diseases. Cell Mol Life Sci. 76:4103–4115. 2019. View Article : Google Scholar : PubMed/NCBI
40	Azizan N, Suter MA, Liu Y and Logsdon CD: RAGE maintains high levels of NFκB and oncogenic Kras activity in pancreatic cancer. Biochem Biophys Res Commun. 493:592–597. 2017. View Article : Google Scholar : PubMed/NCBI
41	Rahimi F, Karimi J, Goodarzi MT, Saidijam M, Khodadadi I, Razavi AN and Nankali M: Overexpression of receptor for advanced glycation end products (RAGE) in ovarian cancer. Cancer Biomark. 18:61–68. 2017. View Article : Google Scholar
42	Tesarova P, Cabinakova M, Mikulova V, Zima T and Kalousova M: RAGE and its ligands in cancer-culprits, biomarkers, or therapeutic targets? Neoplasma. 62:353–364. 2015. View Article : Google Scholar
43	Evankovich J, Lear T, McKelvey A, Dunn S, Londino J, Liu Y, Chen BB and Mallampalli RK: Receptor for advanced glycation end products is targeted by FBXO10 for ubiquitination and degradation. FASEB J. 31:3894–3903. 2017. View Article : Google Scholar : PubMed/NCBI
44	Rittinger K and Ikeda F: Linear ubiquitin chains: Enzymes, mechanisms and biology. Open Biol. 7:pii: 170026. 2017. View Article : Google Scholar : PubMed/NCBI
45	Ao N, Chen Q and Liu G: The small molecules targeting ubiquitin-proteasome system for cancer therapy. Comb Chem High Throughput Screen. 20:403–413. 2017. View Article : Google Scholar : PubMed/NCBI
46	Ding F, Xiao H, Wang M, Xie X and Hu F: The role of the ubiquitin-proteasome pathway in cancer development and treatment. Front Biosci (Landmark Ed). 19:886–895. 2014. View Article : Google Scholar
47	Davis H and Tomlinson I: CDC4/FBXW7 and the 'just enough' model of tumourigenesis. J Pathol. 227:131–135. 2012. View Article : Google Scholar : PubMed/NCBI